| Literature DB >> 20006910 |
Sienmi Du1, Francisco Sandoval, Pauline Trinh, Rhonda R Voskuhl.
Abstract
We studied the effects of combination treatment with an anti-inflammatory agent, interferon (IFN)-beta, and a putative neuroprotective agent, an estrogen receptor (ER)-beta ligand, during EAE. Combination treatment significantly attenuated EAE disease severity, preserved axonal densities in spinal cord, and reduced CNS inflammation. Combining ERbeta treatment with IFNbeta reduced IL-17, while it abrogated IFNbeta-mediated increases in Th1 and Th2 cytokines from splenocytes. Additionally, combination treatment reduced VLA-4 expression on CD4+ T cells, while it abrogated IFNbeta-mediated decreases in MMP-9. Our data demonstrate that combination treatments can result in complex effects that could not have been predicted based on monotherapy data alone. Copyright 2009 Elsevier B.V. All rights reserved.Entities:
Mesh：
Substances：
Year: 2009 PMID： 20006910 PMCID： PMC3037186 DOI： 10.1016/j.jneuroim.2009.11.018
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478